Place de la chimio-embolisation dans le traitement du carcinome hépatocellulaire non résécable

Mickael Lesurtel; Zakiyah Kadry; Thomas Pfammatter; Pierre Alain Clavien

Place de la chimio-embolisation dans le traitement du carcinome hépatocellulaire non résécable

Translated title of the contribution: Transarterial chemoembolization for treatment of hepatocellular carcinoma

Mickael Lesurtel, Zakiyah Kadry, Thomas Pfammatter, Pierre Alain Clavien

Department of Surgery

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Based on the principles of evidence-based medicine, we review the current status of transarterial chemoembolization (TACE) for treatment of unresectable HCC. TACE significantly improves survival compared to symptomatic treatment. Because of the potential deterioration of the liver function after TACE, morbidity and mortality can reach 15% and 6%, respectively. That is the reason why TACE should be advised for only properly selected patients with HCC without vascular invasion or extrahepatic spread. These patients should also have an otherwise well-preserved liver function (mainly Child-Pugh class A-B). Transarterial embolization without chemotherapy is not as efficient as TACE in terms of survival. Adequate research for improvements of technical issues requires inclusion of treated patients in randomized controlled trials.

Translated title of the contribution	Transarterial chemoembolization for treatment of hepatocellular carcinoma
Original language	French
Pages (from-to)	1074-1081
Number of pages	8
Journal	Medecine et Hygiene
Volume	61
Issue number	2438
State	Published - May 21 2003

All Science Journal Classification (ASJC) codes

General Medicine

Cite this

@article{f9e6575c3a3b411a94115a755e416c7c,

title = "Place de la chimio-embolisation dans le traitement du carcinome h{\'e}patocellulaire non r{\'e}s{\'e}cable",

abstract = "Based on the principles of evidence-based medicine, we review the current status of transarterial chemoembolization (TACE) for treatment of unresectable HCC. TACE significantly improves survival compared to symptomatic treatment. Because of the potential deterioration of the liver function after TACE, morbidity and mortality can reach 15% and 6%, respectively. That is the reason why TACE should be advised for only properly selected patients with HCC without vascular invasion or extrahepatic spread. These patients should also have an otherwise well-preserved liver function (mainly Child-Pugh class A-B). Transarterial embolization without chemotherapy is not as efficient as TACE in terms of survival. Adequate research for improvements of technical issues requires inclusion of treated patients in randomized controlled trials.",

author = "Mickael Lesurtel and Zakiyah Kadry and Thomas Pfammatter and Clavien, {Pierre Alain}",

year = "2003",

month = may,

day = "21",

language = "French",

volume = "61",

pages = "1074--1081",

journal = "Medecine et Hygiene",

issn = "0025-6749",

publisher = "Editions Medecine et Hygiene",

number = "2438",

}

TY - JOUR

T1 - Place de la chimio-embolisation dans le traitement du carcinome hépatocellulaire non résécable

AU - Lesurtel, Mickael

AU - Kadry, Zakiyah

AU - Pfammatter, Thomas

AU - Clavien, Pierre Alain

PY - 2003/5/21

Y1 - 2003/5/21

N2 - Based on the principles of evidence-based medicine, we review the current status of transarterial chemoembolization (TACE) for treatment of unresectable HCC. TACE significantly improves survival compared to symptomatic treatment. Because of the potential deterioration of the liver function after TACE, morbidity and mortality can reach 15% and 6%, respectively. That is the reason why TACE should be advised for only properly selected patients with HCC without vascular invasion or extrahepatic spread. These patients should also have an otherwise well-preserved liver function (mainly Child-Pugh class A-B). Transarterial embolization without chemotherapy is not as efficient as TACE in terms of survival. Adequate research for improvements of technical issues requires inclusion of treated patients in randomized controlled trials.

AB - Based on the principles of evidence-based medicine, we review the current status of transarterial chemoembolization (TACE) for treatment of unresectable HCC. TACE significantly improves survival compared to symptomatic treatment. Because of the potential deterioration of the liver function after TACE, morbidity and mortality can reach 15% and 6%, respectively. That is the reason why TACE should be advised for only properly selected patients with HCC without vascular invasion or extrahepatic spread. These patients should also have an otherwise well-preserved liver function (mainly Child-Pugh class A-B). Transarterial embolization without chemotherapy is not as efficient as TACE in terms of survival. Adequate research for improvements of technical issues requires inclusion of treated patients in randomized controlled trials.

UR - http://www.scopus.com/inward/record.url?scp=0038148399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038148399&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0038148399

SN - 0025-6749

VL - 61

SP - 1074

EP - 1081

JO - Medecine et Hygiene

JF - Medecine et Hygiene

IS - 2438

ER -

Place de la chimio-embolisation dans le traitement du carcinome hépatocellulaire non résécable

Abstract

All Science Journal Classification (ASJC) codes

Other files and links

Fingerprint

Cite this